Degeneration of pyramidal projection neurons in Huntington's disease cortex

We examined the distribution of neuropeptide Y immunoreactive local circuit neurons and nonphosphorylated neurofilament (SMI 32) immunoreactive pyramidal projection neurons in superior frontal cortex of patients with Huntington's disease and age‐matched control subjects to determine the histological counterpart of increased neuropeptide Y and decreased glutamate concentrations previously found in the cortex of patients with Huntington's disease. We found no difference between the relative density of neuropeptide Y neurons in Huntingon's disease and control brains in regions where the relative density of SMI 32 immunoreactive neurons was significantly reduced. Animal studies show that cortical local circuit neurons are resistant to N‐methyl‐D‐aspartate‐type excitotoxins such as quinolinic acid. Relative sparing of neuropeptide Y neurons in cerebral cortex with Huntington's disease may, therefore, be a result of excessive N‐methyl‐D‐asparate receptor activation.

[1]  Joseph B. Martin,et al.  Somatostatin and neuropeptide Y concentrations in pathologically graded cases of huntington's disease , 1988, Annals of neurology.

[2]  J. Donoghue,et al.  Localization of glutaminase-like and aspartate aminotransferase-like immunoreactivity in neurons of cerebral neocortex , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[3]  Joseph B. Martin,et al.  Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum , 1986, Neuroscience Letters.

[4]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[5]  J. B. Martin,et al.  Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: A combined immunocytochemical and enzyme histochemical study , 1987, Neuroscience.

[6]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[7]  John H. Morrison,et al.  A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurons in Alzheimer's disease , 1987, Brain Research.

[8]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[9]  A. Parent,et al.  Differential sensitivity of neuropeptide Y, somatostatin and NADPH-diaphorase containing neurons in rat cortex and striatum to quinolinic acid , 1988, Brain Research.

[10]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[11]  T. Kaneko,et al.  Immunohistochemical study of glutaminase‐containing neurons in the cerebral cortex and thalamus of the rat , 1988, The Journal of comparative neurology.

[12]  Joseph B. Martin,et al.  Somatostatin is increased in the basal ganglia in Huntington disease , 1983, Annals of neurology.

[13]  T. Powell,et al.  The basic uniformity in structure of the neocortex. , 1980, Brain : a journal of neurology.

[14]  F. Conti,et al.  Glutamate-positive neurons in the somatic sensory cortex of rats and monkeys , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  M. Beal,et al.  Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in alzheimer's disease , 1988, Annals of neurology.

[16]  D. Choi,et al.  Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. , 1986, Science.

[17]  B. O'neill,et al.  The adrenoleukomyeloneuropathy complex , 1981, Neurology.

[18]  Joseph B. Martin,et al.  Reply from Neil Kowall and colleagues , 1987, Trends in Neurosciences.

[19]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[20]  M. Beal,et al.  Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. , 1987, Brain : a journal of neurology.

[21]  Joseph B. Martin,et al.  Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions , 1989, Synapse.

[22]  P. Emson,et al.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease , 1985, Brain Research.

[23]  K. F. Schroeder,et al.  Morphometric studies of the neuropathological changes in choreatic diseases , 1976, Journal of the Neurological Sciences.

[24]  J. Morrison,et al.  Monoclonal antibody to neurofilament protein (SMI‐32) labels a subpopulation of pyramidal neurons in the human and monkey neocortex , 1989, The Journal of comparative neurology.

[25]  R. Schwarcz,et al.  II: Excitotoxic models for neurodegenerative disorders , 1984 .

[26]  Joseph B. Martin,et al.  An examination of neuropeptide Y postmortem stability in an animal model simulating human autopsy conditions , 1986, Neuroscience Letters.

[27]  G. Reynolds,et al.  Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain , 1987, Neuroscience Letters.

[28]  R. Terry,et al.  STUDIES ON BRAIN BIOPSIES OF PATIENTS WITH HUNTINGTON'S CHOREA , 1974, Journal of neuropathology and experimental neurology.

[29]  D. Choi,et al.  GABAergic neocortical neurons are resistant to NMDA receptor‐mediated injury , 1989, Neurology.

[30]  F. Gallyas,et al.  High-grade intensification of the end-product of the diaminobenzidine reaction for peroxidase histochemistry. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  Joseph B. Martin,et al.  Morphologic and Histochemical Characteristics of a Spared Subset of Striatal Neurons in Huntington's Disease , 1987, Journal of neuropathology and experimental neurology.